Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06054321 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Psychopharmacotherapy for Depressive Patients

Study acronym: BMDD-2022
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Secondary endpoints: 8 to 7v3
  2. Primary endpoint revisedv2 Show 4 more changesShow less
    • Interventions: antidepressant monotherapy group (Drug), stepwise pharamacotherapy (Drug) to antidepressant monotherapy group (Drug), stepwise pharmacotherapy (Drug)
    • Eligibility criteria expanded, about 6 words
    • Secondary endpoints revised (8)
    • Study title shortened, about 10 words
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The primary purpose of this study is to compare the short (12 week) and long-term (1-year) efficacy and the tolerability between stepwise psychopharmacotherapy and antidepressant monotherapy for 12 weeks in adult patients with major depressive disorders, stratified by the multimodal serum biomarker scores.
Trial Details
NCT Number NCT06054321
Lead Sponsor Chonnam National University Hospital
Conditions
(from sponsor)		 Major Depressive Disorder
Related terms Depression, Major Depressive Disorder
Enrollment 400 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov